Scientists at the University of Pittsburgh School of Medicine have discovered ‘the most petite biological molecule‘ that can fully, specifically, and effectively neutralize’ SARS-CoV-2, which is the virus that causes COVID-19.
On Monday, researchers in the journal Cell published a report stated that the antibody is ten times smaller than full-size antibodies and has been used to make Ab8 drugs. The researchers said the drug is a potential prophylactic treatment for SARS-CoV-2 (COVID-19) pandemic.
John Mellors, co-author, and head of the Department of Infectious Diseases at Pitt and UPMC said: Ab8 drug can not only be used as a treatment for COVID-19 infection, but this Ab8 drug can also be used to prevent people from contracting COVID-19 (SARS-CoV-2) infection.
Larger antibodies have worked against other infectious diseases and are well tolerated, which gives us hope that it can be an efficacious therapy for COVID-19 sufferers and protect patients who have never had the coronavirus infection and are not immune.
According to reports, the drug has been experimented in hamsters and mice and proved to be extremely effective in preventing and treating SARS-CoV-2 infection. The researchers also stated that medicine does not bind to human cells. According to them, it may have no adverse side effects on the human body.
Researchers are investigating how to administer the drug, saying that the drug can be inhaled in the form of an aerosol or delivered by superficial inoculation.
Another group of researchers at UTMB (University of Texas Medical Branch) for Exotic Biodefense and Emerging Diseases and GNL (Galveston National Laboratory) tested Ab8 and found that the drug prevented the virus from entering the cell. In the experiment, mice treated with Ab8 had 10 times less infectious virus than those who are untreated. This development was carried out after the world’s largest clinical trial of the coronavirus vaccine developed by the drug manufacturer AstraZeneca was put on hold.
The company said in a statement last week that our standard review method has been initiated and we have voluntarily suspended vaccination to allow an independent committee to review safety data. This is a routine operation. As long as one of the trials has a potential unexplainable disease, it must be investigated to ensure that we maintain the integrity of the trial.
The statement stated: In large case trials; the disease is incidental, but it must be independently checked for careful inspection. We are working to expedite the review of individual incidents to lessen any potential influence on the trial schedule. We are committed to assuring the protection of participants and the highest standards of conduct in our experiments.
The experimental vaccine jointly developed by AstraZeneca Pharmaceuticals and specialists at the University of Oxford is in a leading position in the development of a vaccine to fight the SARS-CoV-2 virus by the end of this year.
STAT, a health news site announced that the Phase 3 trial of the vaccine was shelved after a British participant had a suspicious serious adverse reaction to the drug. STAT pointed out: Although the vaccine developer has not revealed the details of potential unpropitious reactions, the company has downplayed people’s concerns and emphasized that the suspension of the trial is a standard procedure and can be triggered by a medical event. The website reported that the individual concerned hope to recover soon.
In addition to this, an AstraZeneca spokesperson told STAT that currently, only trials in the United Kingdom have been resumed. The company is also conducting Phase 2 or Phase 3 trials in Brazil and the United States, and Phase 1/2 experiments in South Africa.
A statement from the company stated that the Phase 2/3 trial in the United Kingdom has begun to restart, which has been tested on the Covid-19 vaccine developed by AstraZeneca. The news reports stated that the trial is about to resume comes 4 days after it was revealed that the trial was suspended due to suspected severe adverse reactions in a participant.
Michele Meixell, the spokesperson wrote in an email: The company will continue to cooperate with health authorities around the world and also guide other clinical trials to provide a comprehensive, equitable, and non-profit vaccine during this epidemic
AstraZeneca issued a statement on Saturday that the UK’s independent investigation into the incident has ended, and it has informed the British Practitioners and Hygiene Administration (equivalent to the Food and Drug Administration) that the trial can be safely continued. MHRA agreed and gave the green light to restart the test.
The ailment, which caused an international outcry, and occurred in a woman who was in a vaccine arm of British trial, has not been officially revealed, although Pascal Suriot, AstraZeneca CEO told a group of investors on Wednesday that her symptoms were transverse myelitis or rhabdomyolysis; a serious ailment including inflammation of the spinal cord that can cause paralysis, pain, muscle weakness, and bladder problems.
AstraZeneca’s statement stated that information about women’s diseases could not be disclosed. The University of Oxford, which developed the vaccine for COVID-19 treatment, said in a separate report that the nature of the disease could not be disclosed: for the sake of confidentiality of participants.
As part of the review process, the independent committee supervising trials of various other coronavirus vaccines is examining its own data and looking for cases. There are at least 35 vaccines in the clinical trials worldwide, 9 of which are in the final phase 3 of the trial.
Covid-19 has infected more than 10 million people worldwide and claimed more than 4 million lives, while the United States and Europe surpassed China, where the epidemic began in December last year. WHO (World Health Organization) has declared that the COVID-19 has become a dangerous pandemic due to the widespread outbreak and warned that the worst of Covid-19 has not yet arrived. The United Nations also stated that the coronavirus epidemic is the most serious global crisis since World War II. The United States, Brazil, India, Russia, and Peru are the five countries most affected by the number of confirmed cases of the coronavirus.